BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ro H, Min SI, Yang J, Moon KC, Kim YS, Kim SJ, Ahn C, Ha J. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation. Ther Drug Monit. 2012;34:680-685. [PMID: 23149441 DOI: 10.1097/ftd.0b013e3182731809] [Cited by in Crossref: 44] [Cited by in F6Publishing: 16] [Article Influence: 4.9] [Reference Citation Analysis]
Number Citing Articles
1 Larpparisuth N, Skulratanasak P, Vongwiwatana A, Premasathian N. Effect on Dosage Change and Intrapatient Variability After Conversion From Twice-Daily to Once-Daily Tacrolimus Among Thai Kidney Transplant Patients With and Without CYP3A4/5 Inhibitors. Transplant Proc 2019;51:2620-3. [PMID: 31474450 DOI: 10.1016/j.transproceed.2019.02.065] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Shen CL, Yang AH, Lien TJ, Tarng DC, Yang CY. Tacrolimus Blood Level Fluctuation Predisposes to Coexisting BK Virus Nephropathy and Acute Allograft Rejection. Sci Rep 2017;7:1986. [PMID: 28512328 DOI: 10.1038/s41598-017-02140-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
3 Seibert SR, Schladt DP, Wu B, Guan W, Dorr C, Remmel RP, Matas AJ, Mannon RB, Israni AK, Oetting WS, Jacobson PA. Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients. Clin Transplant 2018;32:e13424. [PMID: 30318646 DOI: 10.1111/ctr.13424] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
4 Park Y, Lee H, Eum SH, Kim HD, Ko EJ, Yang CW, Chung BH. Intrapatient Variability in Tacrolimus Trough Levels Over 2 Years Affects Long-Term Allograft Outcomes of Kidney Transplantation. Front Immunol 2021;12:746013. [PMID: 34659243 DOI: 10.3389/fimmu.2021.746013] [Reference Citation Analysis]
5 Oetting WS, Dorr C, Remmel RP, Matas AJ, Israni AK, Jacobson PA. Concepts of Genomics in Kidney Transplantation. Curr Transplant Rep 2017;4:116-23. [PMID: 29123971 DOI: 10.1007/s40472-017-0153-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
6 Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L, Hebral AL, Bellière J, Kamar N. High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation. World J Gastroenterol 2018; 24(16): 1795-1802 [PMID: 29713132 DOI: 10.3748/wjg.v24.i16.1795] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
7 Dorr CR, Oetting WS, Jacobson PA, Israni AK. Genetics of acute rejection after kidney transplantation. Transpl Int 2018;31:263-77. [PMID: 29030886 DOI: 10.1111/tri.13084] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
8 Glick L, Shamy F, Nash M, Sokwala A, Malavade T, Prasad GR, Zaltzman JS. A prospective cohort conversion study of twice-daily to once-daily extended-release tacrolimus: role of ethnicity. Transplant Res. 2014;3:7. [PMID: 24606676 DOI: 10.1186/2047-1440-3-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
9 Herblum J, Dacouris N, Huang M, Zaltzman J, Prasad GVR, Nash M, Chen L. Retrospective Analysis of Tacrolimus Intrapatient Variability as a Measure of Medication Adherence. Can J Kidney Health Dis 2021;8:20543581211021742. [PMID: 34188946 DOI: 10.1177/20543581211021742] [Reference Citation Analysis]
10 Ghareeb M, Gohh RY, Akhlaghi F. Tacrolimus Concentration in Saliva of Kidney Transplant Recipients: Factors Influencing the Relationship with Whole Blood Concentrations. Clin Pharmacokinet 2018;57:1199-210. [PMID: 29330784 DOI: 10.1007/s40262-017-0626-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
11 Larpparisuth N, Pongnatcha T, Panprom P, Promraj R, Premasathian N, Vongwiwatana A. High Intrapatient Variability in Tacrolimus Exposure Calculated Over a Long Period Is Associated With De Novo Donor-Specific Antibody Development and/or Late Rejection in Thai Kidney Transplant Patients Receiving Concomitant CYP3A4/5 Inhibitors. Ther Drug Monit 2021;43:624-9. [PMID: 33278239 DOI: 10.1097/FTD.0000000000000850] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Rojas L, Neumann I, Herrero MJ, Bosó V, Reig J, Poveda JL, Megías J, Bea S, Aliño SF. Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies. Pharmacogenomics J 2015;15:38-48. [PMID: 25201288 DOI: 10.1038/tpj.2014.38] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 8.5] [Reference Citation Analysis]
13 McGillicuddy J, Chandler J, Sox L, Mueller M, Nemeth L, Baliga P, Treiber F. "Smartphone Medication Adherence Saves Kidneys" for Kidney Transplantation Recipients: Protocol for a Randomized Controlled Trial. JMIR Res Protoc 2019;8:e13351. [PMID: 31228175 DOI: 10.2196/13351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Taber DJ, Su Z, Fleming JN, McGillicuddy JW, Posadas-Salas MA, Treiber FA, Dubay D, Srinivas TR, Mauldin PD, Moran WP. Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation. Transplantation. 2017;101:2931-2938. [PMID: 28658199 DOI: 10.1097/tp.0000000000001840] [Cited by in Crossref: 39] [Cited by in F6Publishing: 19] [Article Influence: 7.8] [Reference Citation Analysis]
15 Shen CL, Wu BS, Lien TJ, Yang AH, Yang CY. BK Polyomavirus Nephropathy in Kidney Transplantation: Balancing Rejection and Infection. Viruses 2021;13:487. [PMID: 33809472 DOI: 10.3390/v13030487] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Mo H, Kim SY, Min S, Han A, Ahn S, Min SK, Lee H, Ahn C, Kim Y, Ha J. Association of Intrapatient Variability of Tacrolimus Concentration With Early Deterioration of Chronic Histologic Lesions in Kidney Transplantation. Transplant Direct 2019;5:e455. [PMID: 31321291 DOI: 10.1097/TXD.0000000000000899] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
17 Lee KW, Kim TH, Lee JB, Kim KS, Park JB, Gershkovich P, Yoo SD, Shin S, Shin BS, Kim SJ. Reduced variability in tacrolimus pharmacokinetics following intramuscular injection compared to oral administration in cynomolgus monkeys: Investigating optimal dosing regimens. J Pharmacol Sci 2019;139:65-71. [PMID: 30573325 DOI: 10.1016/j.jphs.2018.05.013] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Qu L, Lu Y, Ying M, Li B, Weng C, Xie Z, Liang L, Lin C, Yang X, Feng S, Wang Y, Shen X, Zhou Q, Chen Y, Chen Z, Wu J, Lin W, Shen Y, Qin J, Xu H, Xu F, Wang J, Chen J, Jiang H, Huang H. Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients. Oncotarget 2017;8:81285-94. [PMID: 29113387 DOI: 10.18632/oncotarget.18150] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
19 González-vílchez F, Crespo-leiro MG, Delgado-jiménez J, Pérez-villa F, Segovia-cubero J, Díaz-molina B, Mirabet-pérez S, Arizón del Prado JM, Blasco-peiró T, Martínez-sellés M, Almenar-bonet L, Garrido-bravo I, Rábago G, Vázquez de Prada JA. Impacto de la variabilidad intrapaciente en la concentración sanguínea de anticalcineurínicos en los resultados del trasplante cardiaco. Revista Española de Cardiología 2022;75:129-40. [DOI: 10.1016/j.recesp.2021.02.004] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Huang Z, Wang J, Qian J, Li Y, Xu Z, Chen M, Tong H. Effects of cytochrome P450 family 3 subfamily A member 5 gene polymorphisms on daunorubicin metabolism and adverse reactions in patients with acute leukemia. Mol Med Rep 2017;15:3493-8. [PMID: 28440407 DOI: 10.3892/mmr.2017.6470] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]